Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAAM Study: Bevacizumab + Pegaptanib versus Monotherapy in AMD
2006-001389-18Phase 2Completed
- Sponsor
- Ludwig Boltzmann Institut für Retinologie und biomikroskopische Laserchirurgie
- Start
- Aug 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in age-related macular degeneration (AMD) comparing Bevacizumab monotherapy, Pegaptanib monotherapy and Bevacizumab + Pegaptanib combination (3 arms). Primary endpoint: Change in retinal thickness. Started Aug 2006; status: completed.
02
Drugs
bevacizumabpegaptanib sodium
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2006-001389-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001389-18.